Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Emergo Therapeutics

Request full access

Emergo is developing treatments to target the release of inflammatory molecules in order to tune down inflammation at its source

Durham, United StatesFounded 2017Biotech & Life Sciences

About Emergo Therapeutics

Emergo Therapeutics is a biopharmaceutical company focused on developing innovative treatments that target the release of inflammatory molecules, aiming to balance the immune response and reduce inflammation at its source. The company operates in the healthcare and pharmaceutical market, primarily serving patients suffering from conditions related to excessive inflammation. Emergo's business model involves conducting rigorous clinical trials to validate the efficacy and safety of its lead compound, norketotifen, which has shown promise in treating influenza and influenza-like illnesses. The company generates revenue through the development and potential commercialization of its therapeutic solutions, as well as through strategic partnerships and licensing agreements. Emergo has successfully completed Phase 1 and Phase 2a clinical trials and is currently advancing to Phase 2b, demonstrating strong market potential and investor confidence. The company's leadership includes experienced professionals such as Jack Bailey, President of GSK Pharmaceuticals USA, who bring valuable expertise to guide its strategic direction.

Source: Dealroom company data

Emergo Therapeutics in the Durham ecosystem

Live from Dealroom

The Emergo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Rex Health Ventures

Series B and later1 investor entered at this stage

  • North Carolina Biotechnology Center
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Emergo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Emergo Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.